%0 Journal Article
%T Efficacy and Safety of Degarelix in Taiwanese Patients with Prostate Cancer Requiring Androgen Deprivation Therapy: An Open-label, Multicenter Phase III Study
%A Chao-Yuan Huang
%A Chih-Shou Chen
%A Hsi-Chin Wu
%A Kun-Hung Shen
%A Ming-Kuen Lai
%A Po-Hui Chiang
%A See-Tong Pang
%A Tony Wu
%A Yen-Chuan Ou
%A Yen-Hwa Chang
%J -
%D 2016
%R https://doi.org/10.18314/gjct.v2i1.73
%X Background: Pivotal phase III data have shown the efficacy and safety of degarelix (240 mg starting dose/80 mg maintenance dose [240/80 mg]) in North American and European patients with prostate cancer (PCa). This open-label, multicenter, single-arm trial has evaluated the efficacy and safety of degarelix in Taiwanese patients with PCa
%U https://www.gratisoa.org/journals/index.php/GJCT/article/view/73